Clinical Trial Update: AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies [Phase 3]

View source ↗

Summary

Phase 3 trial AIM 3 evaluated anemia management with every-3-week dosing and iron optimization in anemic subjects with nonmyeloid malignancies. The study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonmyeloid Malignancies

Drugs mentioned

• EPOETIN ALFA (EPOETIN ALFA)

Snippet

Sponsor: Amgen | Conditions: Cancer | Phase 3 | Status: COMPLETED